Successfully Producing Insoluble Proteins Using Inclusion Bodies

Despite the historically bad reputation of inclusion bodies (IBs), they can often present a more economical option from a bioprocessing perspective. Knowing how to use them effectively and efficiently, though, requires extensive experience with microbial processes using advanced engineering and process development capabilities.

Lonza Pharma & Biotech’s Jonas Mueller, team manager, and Nikolay Krumov, senior project leader, recently hosted the webinar Inclusion Bodies ― Mother Nature’s Help or Hindrance? In it, the pair discussed the pros and cons of soluble and insoluble processes, shared their experiences with isolating, solubilizing, and properly re-folding, and argued that the right approach to insoluble processes can not only be viable at scale but also can offer great opportunities to improve the total process outcome versus soluble production. They also reviewed strategies and future innovation to improve the performance of Lonza’s IB processes.

Download the full article to review the Q&A session held after the event, where the presenters addressed attendee questions about the details of the presentation.